Legend Biotech Corporation (LEGN) Fair Value 2026

LEGN · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.7 /10

32 fundamental signals · 2 models active

Value Trap Risk

SAFE (15/100)

Quick Summary — As of 2026-08-31, Legend Biotech Corporation (LEGN) trades at $20.78, versus a $6.99 median fair value across its 2 active models — 66.4% below the current price. QOC: 6.7/10. Value Trap Risk: 15/100 (SAFE). 2/13 models active.

Key Facts

Ticker
LEGN
Price
$20.78
Quality Score
6.7/10
Value Trap Risk
15/100
Models Active
2/13
Last Updated
Strength: 2 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Legend Biotech Corporation (LEGN) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Legend Biotech Corporation (LEGN) appears overvalued as of : the median of 2 independent fair value estimates is $6.99, 66.4% below the current price of $20.78. Estimates range from $5.24 to $8.73. LEGN scores 6.7/10 on fundamental quality and 15/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.1% versus its own 13-model consensus, across 3,804 rated companies as of 2026-08-31. LEGN’s -66.4% gap is wider than that market norm, and the Biotechnology sector median is -63.9%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Legend Biotech Corporation Stock in 2026? →

What Fair Value Does Each Model Give LEGN?

2 Intrinsic Value Models vs. Current Price ($20.78)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Medium Conviction
 $5.24 -74.8%
Relative · Low Conviction
 $8.73 -58.0%

All Models Active

All 2 models are displayed above.

What Is Legend Biotech Corporation (LEGN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Legend Biotech Corporation's intrinsic value is estimated at $6.99. Trading at its current price of $20.78, the valuation engine raises significant caution: 2 of 2 models flag downside risk, projecting a median implied return of -66.4%.

What Do the Models Say About LEGN?

2 of 13 models are currently active for LEGN. All 2 active models suggest the stock trades above fair value. Taken together, their median fair value for LEGN is $6.99 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does LEGN Rank in Biotechnology?

Among 625 Biotechnology stocks, LEGN ranks #67 by Quality of Company score. CirclFi's QOC score of 6.7/10 evaluates 32 fundamental signals. A score of 6.7 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

Legend Biotech Corporation's positioning within the Biotechnology segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including partnership and licensing deals — shape both the opportunity set and risk profile.

Is LEGN a Value Trap?

CirclFi's Value Trap algorithm assigns LEGN a score of 15/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Legend Biotech Corporation. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Legend Biotech Corporation earns a quality score of 6.7/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

Models cluster within a tight range (+16.8% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every LEGN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across LEGN's 2 active models, average confidence is 24%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Legend Biotech Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

MDGLMadrigal Pharmaceuticals, Inc.QOC 6.7BCYCBicycle Therapeutics plcQOC 6.7XBIOXenetic Biosciences, Inc.QOC 6.7INSMInsmed IncorporatedQOC 6.7OCULOcular Therapeutix, Inc.QOC 6.8CRNXCrinetics Pharmaceuticals, Inc.QOC 6.7DBVTDBV Technologies S.A.QOC 5.4ATOSAtossa Therapeutics, Inc.QOC 4.8NERVMinerva Neurosciences, Inc.QOC 4.0EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: MDGL · BCYC · XBIO · INSM · OCUL · CRNX · DBVT · ATOS · NERV · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to LEGN?

7 companies across all industries closest to LEGN’s Quality of Company score of 6.7/10.

NATNordic American Tankers LimitedQOC 6.7SWAGStran & Company, Inc.QOC 6.7CLVTClarivate PlcQOC 6.7HUNHuntsman CorporationQOC 6.7FKWLFranklin Wireless Corp.QOC 6.7LTCHLatch, Inc.QOC 6.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NAT · SWAG · CLVT · HUN · FKWL · LTCH · NVDA

Where Does LEGN Sit in CirclFi's Biotechnology Rankings?

LEGN is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Legend Biotech Corporation’s Valuation?

What is Legend Biotech Corporation's intrinsic value in 2026?

CirclFi puts Legend Biotech Corporation (LEGN)'s intrinsic value at $6.99 — the median of 2 independent model estimates as of 2026-08-31, ranging from $5.24 to $8.73. The Quality of Company score is 6.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is LEGN overvalued or undervalued right now?

At $20.78, 0 of 2 active models suggest LEGN may be undervalued, while 2 indicate potential overvaluation. The median of all 2 fair value estimates is $6.99, 66.4% below the current price of $20.78 — a consensus view that LEGN is overvalued. The assessment depends on which methodology best fits Legend Biotech Corporation's business model in Biotechnology.

What does a Quality of Company score of 6.7 mean for LEGN?

Legend Biotech Corporation's QOC of 6.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on LEGN?

CirclFi analyzes LEGN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is LEGN a value trap in 2026?

Legend Biotech Corporation's Value Trap score is 15/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Legend Biotech Corporation (LEGN) has a median fair value of $6.99 — 66.4% below the current price of $20.78 — as of 2026-08-31.” Source: circlfi.com/stock/LEGN/ · Methodology
Primary sources for this LEGN valuation
  • Financial statements: Legend Biotech Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001801198) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for LEGN as of ; valuations recomputed .